Read by QxMD icon Read

Dengue vaccine

Lisa Rosenbaum
No abstract text is available yet for this article.
June 13, 2018: New England Journal of Medicine
Saranya Sridhar, Alexander Luedtke, Edith Langevin, Ming Zhu, Matthew Bonaparte, Tifany Machabert, Stephen Savarino, Betzana Zambrano, Annick Moureau, Alena Khromava, Zoe Moodie, Ted Westling, Cesar Mascareñas, Carina Frago, Margarita Cortés, Danaya Chansinghakul, Fernando Noriega, Alain Bouckenooghe, Josh Chen, Su-Peing Ng, Peter B Gilbert, Sanjay Gurunathan, Carlos A DiazGranados
Background In efficacy trials of a tetravalent dengue vaccine (CYD-TDV), excess hospitalizations for dengue were observed among vaccine recipients 2 to 5 years of age. Precise risk estimates according to observed dengue serostatus could not be ascertained because of the limited numbers of samples collected at baseline. We developed a dengue anti-nonstructural protein 1 (NS1) IgG enzyme-linked immunosorbent assay and used samples from month 13 to infer serostatus for a post hoc analysis of safety and efficacy...
June 13, 2018: New England Journal of Medicine
Mohamed Shehata Draz, Manasa Venkataramani, Harini Lakshminarayanan, Ecem Saygili, Maryam Moazeni, Anish Vasan, Yudong Li, Xiaoming Sun, Stephane Hua, Xu G Yu, Hadi Shafiee
Zika virus (ZIKV) is a reemerging flavivirus causing an ongoing pandemic and public health emergency worldwide. There are currently no effective vaccines or specific therapy for Zika infection. Rapid, low-cost diagnostics for mass screening and early detection are of paramount importance in timely management of the infection at the point-of-care (POC). The current Zika diagnostics are laboratory-based and cannot be implemented at the POC particularly in resource-limited settings. Here, we develop a nanoparticle-enhanced viral lysate electrical sensing assay for Zika virus detection on paper microchips with printed electrodes...
June 8, 2018: Nanoscale
Shannon E Brent, Alexander Watts, Martin Cetron, Matthew German, Moritz Ug Kraemer, Isaac I Bogoch, Oliver J Brady, Simon I Hay, Maria I Creatore, Kamran Khan
Objective: To examine the potential for international travel to spread yellow fever virus to cities around the world. Methods: We obtained data on the international flight itineraries of travellers who departed yellow fever-endemic areas of the world in 2016 for cities either where yellow fever was endemic or which were suitable for viral transmission. Using a global ecological model of dengue virus transmission, we predicted the suitability of cities in non-endemic areas for yellow fever transmission...
May 1, 2018: Bulletin of the World Health Organization
Ravi Kant Rajpoot, Rahul Shukla, Upasana Arora, Sathyamangalam Swaminathan, Navin Khanna
Dengue is a significant public health problem worldwide, caused by four antigenically distinct mosquito-borne dengue virus (DENV) serotypes. Antibodies to any given DENV serotype which can afford protection against that serotype tend to enhance infection by other DENV serotypes, by a phenomenon termed antibody-dependent enhancement (ADE). Antibodies to the viral pre-membrane (prM) protein have been implicated in ADE. We show that co-expression of the envelope protein of all four DENV serotypes, in the yeast Pichia pastoris, leads to their co-assembly, in the absence of prM, into tetravalent mosaic VLPs (T-mVLPs), which retain the serotype-specific antigenic integrity and immunogenicity of all four types of their monomeric precursors...
June 5, 2018: Scientific Reports
Ilane Hernandez-Morales, Marnix Van Loock
Dengue is the most important mosquito-borne viral disease in the world, representing a major unmet medical need and a growing public health concern. The disease imposes a heavy burden to the affected individuals, to the health care systems, and to the economies of endemic countries. Vector control is the most widespread tool to curb dengue epidemics, but has been insufficient. Therefore, additional means such as vaccines and antivirals are required to aid in a coordinated response. The discovery and development of small molecule dengue virus inhibitors as a tool to prevent and/or treat dengue disease faces major hurdles in combining pan-serotypic efficacy, safety, and optimal drug-like properties...
2018: Advances in Experimental Medicine and Biology
Jenny G Low, Rene Gatsinga, Subhash G Vasudevan, Aruna Sampath
Dengue fever is a leading cause of illness and mortality in the tropics and subtropics. There are no therapeutics currently available and a recently approved vaccine is not very efficacious demanding an urgent need to develop an effective antiviral. The path to successful dengue drug development depends on availability of relevant preclinical testing models and better understanding of dengue pathogenesis. In recent years, efforts to develop dengue therapeutics have focused on both repurposing approved drugs as well as discovery of new chemical entities that act via virus or host targeted mechanisms...
2018: Advances in Experimental Medicine and Biology
Anuja Mathew
The focus of this review is to discuss findings in the last 10 years that have advanced our understanding of human NK cell responses to dengue virus. We will review recently identified interactions of activating and inhibitory receptors on NK cells with dengue virus, human NK responses to natural dengue infection and highlight possible interactions by which NK cells may shape adaptive immune responses. T cell responses to natural dengue infection will be reviewed by Laura Rivino in Chap. 17 . With the advent of numerous dengue vaccine clinical trials, we will also review T and NK cell immune responses to dengue virus vaccination...
2018: Advances in Experimental Medicine and Biology
Eduardo Alves Dos Santos, Katja Fink
The current status of animal models in the study of dengue and Zika are covered in this review. Mouse models deficient in IFN signaling are used to overcome the natural resistance of mice to non-encephalitic flaviviruses. Conditional IFNAR mice and non-human primates (NHP) are useful immuno-competent models. Sterile immunity after dengue vaccination is not observed in NHPs. Placental and fetal development in NHPs is similar to humans, facilitating studies on infection-mediated fetal impairment.
2018: Advances in Experimental Medicine and Biology
David A Jans, Alexander J Martin
Signal-dependent movement of proteins into and out of the nucleus through the importin superfamily of transporters is central to the replication of many viruses in infected cells, including RNA viruses such as the flavivirus Dengue virus (DENV). DENV non-structural protein 5 (NS5) traffics into and out of the host cell nucleus/nucleolus, being observed in the nucleus, although to differing extents, very early in infection in the case of all 4 DENV serotypes; with results from both reverse genetics and inhibitor studies indicating that this trafficking is critical to DENV infection...
2018: Advances in Experimental Medicine and Biology
Daniel Watterson, Naphak Modhiran, David A Muller, Katryn J Stacey, Paul R Young
Recent structural and functional advances provide fresh insight into the biology of the dengue virus non-structural protein, NS1 and suggest new avenues of research. The work of our lab and others have shown that the secreted, hexameric form of NS1 has a systemic toxic effect, inducing inflammatory cytokines and acting directly on endothelial cells to produce the hallmark of dengue disease, vascular leak. We also demonstrated that NS1 exerts its toxic activity through recognition by the innate immune receptor TLR4, mimicking the bacterial endotoxin LPS...
2018: Advances in Experimental Medicine and Biology
Emily N Gallichotte, Ralph S Baric, Aravinda M de Silva
Dengue viruses (DENV) are mosquito-borne positive sense RNA viruses in the family Flaviviridae. The four serotypes of DENV (DENV1, DENV2, DENV3, DENV4) are widely distributed and it is estimated over a third of the world's population is at risk of infection [4]. While the majority of infections are asymptomatic, DENV infection can cause a spectrum of disease, from mild flu-like symptoms, to the more severe DENV hemorrhagic fever and shock syndrome [24]. Over the past 20 years, there have been intense efforts to develop a tetravalent live-attenuated DENV vaccine [36]...
2018: Advances in Experimental Medicine and Biology
Claudia Ohst, Sandra Saschenbrecker, Konstanze Stiba, Katja Steinhagen, Christian Probst, Christiane Radzimski, Erik Lattwein, Lars Komorowski, Winfried Stöcker, Wolfgang Schlumberger
Climate change, increased urbanization and international travel have facilitated the spread of mosquito vectors and the viral species they carry. Zika virus (ZIKV) is currently spreading in the Americas, while dengue virus (DENV) and chikungunya virus (CHIKV) have already become firmly established in most tropical and also many non-tropical regions. ZIKV, DENV and CHIKV overlap in their endemic areas and cause similar clinical symptoms, especially in the initial stages of infection. Infections with each of these viruses can lead to severe complications, and co-infections have been reported...
2018: Advances in Experimental Medicine and Biology
Eduardo Massad, Marcos Amaku, Francisco Antonio Bezerra Coutinho, Claudio José Struchiner, Luis Fernandez Lopez, Giovanini Coelho, Annelies Wilder-Smith, Marcelo Nascimento Burattini
Aedes aegypti, historically known as yellow fever (YF) mosquito, transmits a great number of other viruses such as Dengue, West Nile, Chikungunya, Zika, Mayaro and perhaps Oropouche, among others. Well established in Africa and Asia, Aedes mosquitoes are now increasingly invading large parts of the American continent, and hence the risk of urban YF resurgence in the American cities should because of great concern to public health authorities. Although no new urban cycle of YF was reported in the Americas since the end of an Aedes eradication programme in the late 1950s, the high number of non-vaccinated individuals that visit endemic areas, that is, South American jungles where the sylvatic cycle of YF is transmitted by canopy mosquitoes, and return to Aedes-infested urban areas, increases the risk of resurgence of the urban cycle of YF...
May 30, 2018: Epidemiology and Infection
Hasan Bakhshi, Anna-Bella Failloux, Sedigheh Zakeri, Abbasali Raz, Navid Dinparast Djadid
Mosquito-borne viral diseases (MBVDs) have a complex biological cycle involving vectors and vertebrate hosts. These viruses are responsible for many deadly diseases worldwide. Although MBVDs threaten mostly developing countries, there is growing evidence indicating that they are also of concern in western countries where local transmission of arboviruses such as West Nile, Zika, Chikungunya and Dengue viruses have been recently reported. The rapid rise in human infections caused by these viruses is attributed to rapid climate change and travel facilities...
May 26, 2018: Infection, Genetics and Evolution
Jesica A Swanstrom, Sandra Henein, Jessica A Plante, Boyd L Yount, Douglas G Widman, Emily N Gallichotte, Hansi J Dean, Jorge E Osorio, Charalambos D Partidos, Aravinda M de Silva, Ralph S Baric
Background: Dengue virus serotypes 1-4 (DENV-1-4) are the most common vector-borne viral pathogens of humans and the etiological agents of dengue fever and dengue hemorrhagic syndrome. A live-attenuated tetravalent dengue vaccine (TDV) developed by Takeda Vaccines has recently progressed to phase 3 safety and efficacy evaluation. Methods: We analyzed the qualitative features of the neutralizing antibody (nAb) response induced in naive and DENV-immune individuals after TDV administration...
May 25, 2018: Journal of Infectious Diseases
Maïna L'Azou, Jade Assoukpa, Karen Fanouillere, Eric Plennevaux, Matthew Bonaparte, Alain Bouckenooghe, Carina Frago, Fernando Noriega, Betzana Zambrano, R Leon Ochiai, Bruno Guy, Nicholas Jackson
Dengue seroprevalence data in the literature is limited and the available information is difficult to compare between studies because of the varying survey designs and methods used. We assessed dengue seropositivity across 14 countries using data from 15 trials conducted during the development of a tetravalent dengue vaccine between October 2005 and February 2014. Participants' dengue seropositivity (n=8592) was determined from baseline (before vaccination) serum samples at two centralized laboratories with the plaque reduction neutralization test (PRNT50)...
May 23, 2018: Transactions of the Royal Society of Tropical Medicine and Hygiene
Laura S Muñoz, Maria A Garcia, Eliza Gordon-Lipkin, Beatriz Parra, Carlos A Pardo
Emerging viral infections of the nervous system represent a major global public health concern in the 21st century. They are caused primarily by RNA viruses and are mostly associated with acute or subacute encephalitis. The spectrum of associated central or peripheral nervous system disorders is broad, and results either from a direct viral effect or due to the host immune responses against the infection. Emerging viral infections impose substantial neurological morbidity and mortality, particularly in low- and middle-income regions...
April 2018: Seminars in Neurology
Lisa A Jackson, Richard Rupp, Athanasia Papadimitriou, Derek Wallace, Marsha Raanan, Kelley J Moss
BACKGROUND: As part of the ongoing search for an effective dengue vaccine, Takeda performed a phase 1b study to investigate the safety and immunogenicity of an early low-dose tetravalent dengue vaccine candidate formulation (LD-TDV), based on an attenuated serotype 2 backbone, when administered intradermally with an injector device (PharmaJet®), or needle-syringe. METHODS: The study was performed in two centers in the US, in healthy 18-45 year old subjects with no history of dengue vaccination or disease...
May 19, 2018: Vaccine
Kathryn B Anderson, Timothy P Endy, Stephen J Thomas
Dengue virus infections cause a substantial public health burden in tropical and subtropical regions. A single dengue vaccine has been approved by regulatory authorities in 19 countries, but concerns regarding vaccine safety in people who are dengue naive at the time of immunisation has introduced uncertainty into the vaccine's future. As other dengue vaccines complete or enter large-scale efficacy trials, we argue that foundational work by Sabin, historic epidemiological observations of dengue outbreaks, and prospective cohort studies in Asia and the Americas indicate that modifications must be made to the methods of assessing dengue vaccines...
May 18, 2018: Lancet Infectious Diseases
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"